Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Oncotelic Issues Year End Message to Shareholders
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing and DAO capabilities being built with…